# US 2021/0069237 A1 · Pharmaceutical compositions comprising heparinoids and methods for preparing thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069237 A1
- Document ID: US20210069237A1
- Status: Published application
- Kind: A1
- Application number: 17/009,318
- Filed: 2020-09-01
- Published: 2021-03-11
- Earliest claimed: 2019-09-09
- Assignees: Harrow IP, LLC
- Applicants: Harrow IP, LLC
- Inventors: Dennis Elias Saadeh
- Web page: https://patentgrep.com/patent/US20210069237A1

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical compositions are described herein, among others, the compositions comprising anhydrous suspensions of a therapeutically effective quantity of a heparinoid, or a derivative or analog thereof, and to methods of preparing and using such compositions. The use of various heparinoids for these purposes is disclosed, such as pentosan, heparin, hyaluronic acid, chondroitin, and pharmaceutically acceptable salts thereof. Methods for fabricating the compositions and using them are also described.

## Claims

### Claim 1

A pharmaceutical composition formulated as an anhydrous suspension comprising:
(a) a dispersed phase comprising a therapeutically effective quantity of a pharmaceutically acceptable heparinoid; and
(b) an anhydrous dispersion medium optionally comprising at least one pharmaceutically acceptable surfactant, solubilizing agent, and/or suspending agent,
wherein the dispersed phase is dispersed within the dispersion medium.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the heparinoid is selected from the group consisting of pentosan, heparin, hyaluronic acid, chondroitin, pharmaceutically acceptable salts thereof, and any combination thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the heparinoid is pentosan polysulfate sodium.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the concentration of pentosan polysulfate sodium in the composition is between about 0.5 mass % and about 10.0 mass %.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anhydrous dispersion medium comprises at least one vegetable oil or at least one medium chain triglyceride, or any combination thereof.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the vegetable oil is selected from the group consisting of castor oil, soybean oil, coconut oil, avocado oil, olive oil, almond oil, and combinations thereof.

### Claim 7 (depends on 5)

The pharmaceutical composition of claim 5, wherein the medium chain triglyceride is a triglyceride having at least two of the three fatty acid moieties that are derived from saturated open-chain acids having between 6 and 12 carbon atoms.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the saturated open-chain acids are selected from the group consisting of caprylic acid and caproic acid.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the surfactant, solubilizing agent, and/or suspending agent is selected from the group consisting of non-ionic polyoxyethlene-polyoxypropylene block copolymers, a water-soluble derivative of cellulose, optionally partially cross-linked polyacrylates, polyoxyethylene sorbitan monolaurates, glyceryl distearate, triglycerol monooleate, glyceryl isostearate, polyoxyethylene sorbitan monopalmitates, polyoxyethylene sorbitan monostearates, and polyoxyethylene sorbitan monooleates.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the non-ionic polyoxyethlene-polyoxypropylene block copolymer is poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the water-soluble derivative of cellulose is selected from the group consisting of carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9, wherein the solubilizing agent and/or suspending agent is polyoxyethylene (20) sorbitan monooleate.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, further comprising at least one taste modifier selected from the group consisting of sweeteners, flavoring agents, and anesthetic agents.

### Claim 14

A pharmaceutical composition comprising a therapeutically effective quantity of a pharmaceutically acceptable heparinoid and an excipient that enables delayed release or sustained release of the heparinoid.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the excipient comprises a polyacrylate dispersion or at least one water-soluble polymer selected from the group consisting of methylcellulose and hydroxypropyl methylcellulose, wherein the composition is formulated as a delayed release suspension or as an encapsulated solid product.

### Claim 16 (depends on 1)

A method for treating, preventing or alleviating interstitial cystitis in a patient in need of such treatment comprising orally administering to the subject the composition of claim 1.

### Claim 17

A method for treating, preventing or alleviating osteoarthritis comprising administering to the patient by an injection an aqueous composition comprising a therapeutically effective quantity of a pharmaceutically acceptable heparinoid, wherein the injection is selected from the group consisting of an intravenous injection, intramuscular injection and intraarticular injection.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the heparinoid is selected from the group consisting of pentosan, heparin, hyaluronic acid, chondroitin, pharmaceutically acceptable salts thereof, and any combination thereof.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the heparinoid is pentosan polysulfate sodium.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the concentration of pentosan polysulfate sodium in the composition is between about 5.0 mass % and about 20.0 mass %.

### Claim 21

A pharmaceutical composition formulated as an anhydrous suspension comprising:
(a) a dispersed phase comprising a therapeutically effective quantity of a pharmaceutically acceptable heparinoid; and
(b) an anhydrous dispersion medium;
wherein the concentration of heparinoid in the suspension does not deviate by more than ±10%, after storage at room temperature for at least 30 days.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the concentration of heparinoid in the suspension does not deviate by more than ±10%, after storage at room temperature for at least 60 days.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the concentration of heparinoid in the suspension does not deviate by more than ±10%, after storage at room temperature for at least 90 days.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the concentration of heparinoid in the suspension does not deviate by more than ±10%, after storage at room temperature for at least 180 days.

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, wherein the heparinoid is selected from the group consisting of pentosan, heparin, hyaluronic acid, chondroitin, pharmaceutically acceptable salts thereof, and any combination thereof.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the heparinoid is pentosan polysulfate sodium.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the concentration of pentosan polysulfate sodium in the composition is between about 0.5 mass % and about 10.0 mass %.

### Claim 28 (depends on 21)

The pharmaceutical composition of claim 21, wherein the anhydrous dispersion medium comprises at least one vegetable oil or at least one medium chain triglyceride, or any combination thereof.

### Claim 29 (depends on 1)

The pharmaceutical composition of claim 1, wherein the heparinoid has the polydispersity index of 2.0 or less.
